SEC Filings
Abbott CEO's Change-In-Control Agreement Will Expire While Other Executives Get Extensions
The other named executive officers' agreements will run through December 31, 2028, under an existing extension provision.
Abbott Laboratories (ABT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The other named executive officers' agreements will run through December 31, 2028, under an existing extension provision.
SEC Filings
The preliminary reallocation lifts Abbott's amortization schedule for 2026 through 2030, and the company says the final split could differ materially.
Earnings
Robert Ford defended the planned nutrition separation on the earnings call, then took questions on a sales-guidance cut and infant-formula litigation.
SEC Filings
The maker of Similac and Ensure would become a separate public company, with Abbott keeping about $42 billion in sales.
Earnings
Adjusted earnings rose to $1.42 a share as Exact Sciences lifted sales, while amortization, interest and settlements cut reported profit.